Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor?
Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor?
We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as second- (113, 5%) or third-line (111, 5%) therapy. The median PFS was significantly higher in patients with BMI ≥ 25 (9.9 vs. 7.6 months, p < 0.001). The median OS was higher in the BMI ≥ 25 subgroup (30.7 vs. 11.0 months, p = 0.003). As third-line therapy, both median PFS (9.2 months vs. 3.9 months, p = 0.029) and OS (39.4 months vs. 11.5 months, p = 0.039) were longer in patients with BMI ≥ 25. BMI was a significant predictor for both PFS and OS at multivariate analysis. We showed that a BMI ≥ 25 correlates with longer survival in patients receiving cabozantinib. BMI can be easily assessed and should be included in current prognostic criteria for advanced RCC.
Body mass index, Cabozantinib, Obesity, Prognosis, Real-world data, Renal cell carcinoma, Targeted therapy
Santoni, Matteo
317ff6c0-4762-4111-926d-463f2b0a5faf
Massari, Francesco
0a1a93c0-27fc-49ae-b21b-a4208f5893c0
Bracarda, Sergio
1727bca6-5a9c-4c3d-9488-4a137f00c1a8
Procopio, Giuseppe
c6b7da9c-603a-41af-8c9f-7d46f1e9bf49
Milella, Michele
4787b7b5-41d2-4f67-968d-8a10dacb6104
De Giorgi, Ugo
86c9f3a7-1680-4a3f-a34f-32cab5d47b4f
Basso, Umberto
1bab6552-482c-4573-b186-82f50a49d0a4
Aurilio, Gaetano
4ff20f6b-fc87-48ff-833b-bec24a6158ef
Incorvaia, Lorena
1104bd58-4f9d-4977-af55-34a28df6d102
Martignetti, Angelo
8246809b-3e2b-4472-81f2-524b9bfc6a79
Rizzo, Mimma
36fee82a-b96c-4dea-b5cc-ec42d2299d2b
Cartenì, Giacomo
83a826ad-8116-44b9-8cdf-4887a985df77
Grande, Enrique
41136eb3-a48d-4e60-82b6-7d7b423f4a20
Matrana, Marc R
39b427e3-0f7d-4c4c-ab7e-6283f6846e36
Crabb, Simon J
bcd1b566-7677-4f81-8429-3ab0e85f8373
Vau, Nuno
9f014a96-4d40-4563-bc5c-1383ac4dbecd
Sorgentoni, Giulia
b27c8217-7c33-48cc-b26d-1188f9068c81
Cimadamore, Alessia
65caccc5-0cee-43fc-a637-2ce33241658f
Montironi, Rodolfo
f830a00b-e301-40ce-909d-96e5df064774
Battelli, Nicola
d14b9f9b-359f-4261-9088-ce723ca105d9
18 January 2021
Santoni, Matteo
317ff6c0-4762-4111-926d-463f2b0a5faf
Massari, Francesco
0a1a93c0-27fc-49ae-b21b-a4208f5893c0
Bracarda, Sergio
1727bca6-5a9c-4c3d-9488-4a137f00c1a8
Procopio, Giuseppe
c6b7da9c-603a-41af-8c9f-7d46f1e9bf49
Milella, Michele
4787b7b5-41d2-4f67-968d-8a10dacb6104
De Giorgi, Ugo
86c9f3a7-1680-4a3f-a34f-32cab5d47b4f
Basso, Umberto
1bab6552-482c-4573-b186-82f50a49d0a4
Aurilio, Gaetano
4ff20f6b-fc87-48ff-833b-bec24a6158ef
Incorvaia, Lorena
1104bd58-4f9d-4977-af55-34a28df6d102
Martignetti, Angelo
8246809b-3e2b-4472-81f2-524b9bfc6a79
Rizzo, Mimma
36fee82a-b96c-4dea-b5cc-ec42d2299d2b
Cartenì, Giacomo
83a826ad-8116-44b9-8cdf-4887a985df77
Grande, Enrique
41136eb3-a48d-4e60-82b6-7d7b423f4a20
Matrana, Marc R
39b427e3-0f7d-4c4c-ab7e-6283f6846e36
Crabb, Simon J
bcd1b566-7677-4f81-8429-3ab0e85f8373
Vau, Nuno
9f014a96-4d40-4563-bc5c-1383ac4dbecd
Sorgentoni, Giulia
b27c8217-7c33-48cc-b26d-1188f9068c81
Cimadamore, Alessia
65caccc5-0cee-43fc-a637-2ce33241658f
Montironi, Rodolfo
f830a00b-e301-40ce-909d-96e5df064774
Battelli, Nicola
d14b9f9b-359f-4261-9088-ce723ca105d9
Santoni, Matteo, Massari, Francesco, Bracarda, Sergio, Procopio, Giuseppe, Milella, Michele, De Giorgi, Ugo, Basso, Umberto, Aurilio, Gaetano, Incorvaia, Lorena, Martignetti, Angelo, Rizzo, Mimma, Cartenì, Giacomo, Grande, Enrique, Matrana, Marc R, Crabb, Simon J, Vau, Nuno, Sorgentoni, Giulia, Cimadamore, Alessia, Montironi, Rodolfo and Battelli, Nicola
(2021)
Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor?
Diagnostics, 11 (1), [138].
(doi:10.3390/diagnostics11010138).
Abstract
We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as second- (113, 5%) or third-line (111, 5%) therapy. The median PFS was significantly higher in patients with BMI ≥ 25 (9.9 vs. 7.6 months, p < 0.001). The median OS was higher in the BMI ≥ 25 subgroup (30.7 vs. 11.0 months, p = 0.003). As third-line therapy, both median PFS (9.2 months vs. 3.9 months, p = 0.029) and OS (39.4 months vs. 11.5 months, p = 0.039) were longer in patients with BMI ≥ 25. BMI was a significant predictor for both PFS and OS at multivariate analysis. We showed that a BMI ≥ 25 correlates with longer survival in patients receiving cabozantinib. BMI can be easily assessed and should be included in current prognostic criteria for advanced RCC.
Text
diagnostics-1067059 revised AC MS Jan15
- Accepted Manuscript
More information
Accepted/In Press date: 14 January 2021
Published date: 18 January 2021
Additional Information:
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords:
Body mass index, Cabozantinib, Obesity, Prognosis, Real-world data, Renal cell carcinoma, Targeted therapy
Identifiers
Local EPrints ID: 447026
URI: http://eprints.soton.ac.uk/id/eprint/447026
ISSN: 2075-4418
PURE UUID: 6b64f402-b6bb-4100-a323-1bf088c12449
Catalogue record
Date deposited: 02 Mar 2021 17:30
Last modified: 17 Mar 2024 02:57
Export record
Altmetrics
Contributors
Author:
Matteo Santoni
Author:
Francesco Massari
Author:
Sergio Bracarda
Author:
Giuseppe Procopio
Author:
Michele Milella
Author:
Ugo De Giorgi
Author:
Umberto Basso
Author:
Gaetano Aurilio
Author:
Lorena Incorvaia
Author:
Angelo Martignetti
Author:
Mimma Rizzo
Author:
Giacomo Cartenì
Author:
Enrique Grande
Author:
Marc R Matrana
Author:
Nuno Vau
Author:
Giulia Sorgentoni
Author:
Alessia Cimadamore
Author:
Rodolfo Montironi
Author:
Nicola Battelli
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
